BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.73 USD | +0.93% |
|
-3.07% | +25.72% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 168.8 | 382.4 | 1,790 | 878.8 | 767 | 970 | - | - |
| Enterprise Value (EV) 1 | 76.71 | 260.9 | 1,381 | 570 | 280.6 | 658.8 | 741.5 | 870.3 |
| P/E ratio | -3.4 x | -6.75 x | -22.8 x | -7.79 x | -3.56 x | -4.29 x | -4.07 x | -4.12 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 12.2 x | 36.8 x | 153 x | 60.8 x | 28.4 x | 34.7 x | 34.9 x | 20.2 x |
| EV / Revenue | 5.56 x | 25.1 x | 118 x | 39.4 x | 10.4 x | 23.6 x | 26.7 x | 18.1 x |
| EV / EBITDA | -3.03 x | -5.15 x | -21.5 x | -5.05 x | -1.53 x | -3.18 x | -2.99 x | -3.26 x |
| EV / FCF | -2.54 x | -13.7 x | -82.1 x | -5.42 x | -4.42 x | -3.12 x | -2.91 x | -3.31 x |
| FCF Yield | -39.3% | -7.28% | -1.22% | -18.4% | -22.6% | -32% | -34.4% | -30.2% |
| Price to Book | - | - | 4.41 x | 3.24 x | 2.07 x | 3.63 x | 18.5 x | - |
| Nbr of stocks (in thousands) | 17,903 | 21,305 | 29,400 | 29,689 | 42,422 | 42,673 | - | - |
| Reference price 2 | 9.430 | 17.95 | 60.87 | 29.60 | 18.08 | 22.73 | 22.73 | 22.73 |
| Announcement Date | 10/03/20 | 11/03/21 | 01/03/22 | 28/02/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.8 | 10.39 | 11.7 | 14.46 | 26.98 | 27.96 | 27.8 | 48.05 |
| EBITDA 1 | -25.34 | -50.68 | -64.21 | -113 | -183.4 | -207.4 | -247.8 | -267.4 |
| EBIT 1 | -26.3 | -51.96 | -65.62 | -116.7 | -189.9 | -235.3 | -271.6 | -292.5 |
| Operating Margin | -190.56% | -500.1% | -560.98% | -806.56% | -704.13% | -841.48% | -976.74% | -608.79% |
| Earnings before Tax (EBT) 1 | -30.86 | -51.73 | -68.48 | -114.2 | -179.2 | -232.9 | -269.7 | -289.9 |
| Net income 1 | -30.61 | -51.01 | -66.82 | -112.7 | -180.7 | -228.2 | -265.4 | -289.5 |
| Net margin | -221.78% | -490.95% | -571.25% | -779.35% | -669.72% | -816.14% | -954.48% | -602.6% |
| EPS 2 | -2.770 | -2.660 | -2.670 | -3.800 | -5.080 | -5.301 | -5.586 | -5.512 |
| Free Cash Flow 1 | -30.17 | -18.99 | -16.82 | -105.1 | -63.56 | -210.9 | -254.8 | -263.2 |
| FCF margin | -218.59% | -182.76% | -143.83% | -726.67% | -235.61% | -754.43% | -916.27% | -547.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 10/03/20 | 11/03/21 | 01/03/22 | 28/02/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.333 | 3.771 | 3.86 | 4.378 | 3.04 | 3.185 | 4.896 | 11.4 | 5.352 | 5.331 | 6.033 | 6.292 | 6.337 | 7.435 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.29 | -18.02 | -27.38 | -27.3 | -29.76 | -32.21 | -41.8 | -43.11 | -50.8 | -54.24 | -55.04 | -58.14 | -60.55 | -60.76 | -75.5 |
| Operating Margin | -329.89% | -477.94% | -709.4% | -623.57% | -978.91% | -1,011.33% | -853.82% | -378.27% | -949.12% | -1,017.35% | -912.22% | -924.03% | -955.37% | -817.2% | -1,510% |
| Earnings before Tax (EBT) 1 | -15.09 | -18.78 | -27.98 | -27.28 | -28.58 | -30.4 | -39.68 | -43.12 | -47.63 | -48.78 | -55.13 | -58.46 | -60.43 | -61.42 | -71.3 |
| Net income 1 | -14.68 | -18.04 | -27.56 | -26.83 | -28.35 | -29.98 | -39.06 | -42.6 | -49.9 | -49.1 | -53.99 | -57.36 | -60.08 | -60.53 | -71.3 |
| Net margin | -338.75% | -478.31% | -714.09% | -612.79% | -932.47% | -941.22% | -797.88% | -373.81% | -932.32% | -921.01% | -894.9% | -911.74% | -947.99% | -814.08% | -1,426% |
| EPS 2 | -0.5900 | -0.6300 | -0.9300 | -0.9000 | -0.9600 | -1.010 | -1.300 | -1.410 | -1.260 | -1.160 | -1.282 | -1.349 | -1.385 | -1.373 | -1.440 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 04/11/21 | 01/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 28/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 20/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 92.1 | 121 | 409 | 309 | 486 | 311 | 229 | 99.6 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -30.2 | -19 | -16.8 | -105 | -63.6 | -211 | -255 | -263 |
| ROE (net income / shareholders' equity) | - | - | -30.3% | -36.5% | -56.3% | -66.2% | -157% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 13.80 | 9.130 | 8.740 | 6.260 | 1.230 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.56 | 1.2 | 2.03 | 19 | 2.93 | 2.65 | 2.58 | 3.68 |
| Capex / Sales | 11.27% | 11.55% | 17.35% | 131.28% | 10.86% | 9.48% | 9.26% | 7.65% |
| Announcement Date | 10/03/20 | 11/03/21 | 01/03/22 | 28/02/23 | 20/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
22.73
USD
Average target price
43.99
USD
Spread / Average Target
+93.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.72% | 970M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BCYC Stock
- Financials Bicycle Therapeutics plc
